Demonstration Formulary
3 Respiratory system
03-07 Dornase alfa
Links
BCICB Asthma Treatment Guidelines - Adolescents 12-17 years old - BCICB Asthma Treatment Guidelines - Adults 18+
- BCICB Asthma Treatment Guidelines For Children Under 12
- BCICB COPD Inhaler Treatment Guidelines
- BCICB Difficult Asthma Referral Pathway - Adults 18+
- Clinical Commissioning Policy: Ivacaftor for Cystic Fibrosis (named mutations)
- COVID-19: information for the respiratory community
- Greener Inhaler Guide Switching Information
- How to improve respiratory control in asthma and COPD
- NICE CG115: Chronic obstructive pulmonary disease in over 16s: diagnosis and management
- NICE TA10: Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma
- NICE TA138: Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and over
- NICE TA266: Cystic fibrosis - mannitol dry powder for inhalation (TA266)
- NICE TA38: Inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years)
- NICE TA398: Lumacaftor-ivacaftor for treating cystic fibrosis homozygous for the F508del mutation
- TA266: Mannitol dry powder for inhalation for treating cystic fibrosis